March 21, 2022
Biopharmaceutical company Amgen has agreed to drop its patent infringement suit against its rivals, Pfizer and Hospira, asking a Delaware federal judge Monday to end the two-year feud over claims of their post-chemotherapy treatment being nearly identical to Amgen's Neulasta.
February 12, 2020
Pfizer Inc. and Hospira Inc. infringed an Amgen Inc. patent when seeking to get its biosimilar of Amgen's blockbuster anti-infection medicine Neulasta on the market before the patent expired, the biologic maker told a Delaware federal court.